CY1118455T1 - Νεες θεραπευτικες προσεγγισεις για θεραπεια νευροφλεγμονωδων καταστασεων - Google Patents
Νεες θεραπευτικες προσεγγισεις για θεραπεια νευροφλεγμονωδων καταστασεωνInfo
- Publication number
- CY1118455T1 CY1118455T1 CY20171100003T CY171100003T CY1118455T1 CY 1118455 T1 CY1118455 T1 CY 1118455T1 CY 20171100003 T CY20171100003 T CY 20171100003T CY 171100003 T CY171100003 T CY 171100003T CY 1118455 T1 CY1118455 T1 CY 1118455T1
- Authority
- CY
- Cyprus
- Prior art keywords
- therapeutic
- neuroffic
- diseases
- approaches
- new
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση αφορά σε νέες συνθέσεις οι οποίες μπορεί να χρησιμοποιηθούν για τη θεραπεία νευροφλεγμονής, ιδιαιτέρως σε υποκείμενα που έχουν νευροεκφυλιστική, αυτοάνοση, μολυσματώδη, τοξική ή τραυματική διαταραχή. Ειδικότερα, η εφεύρεση αφορά σε συνδυασμένες θεραπείες για θεραπεία νευροφλεγμονής. Η εφεύρεση επίσης αποκαλύπτει νέες μεθόδους για θεραπεία παθολογικών καταστάσεων νευροφλεγμονής σε ένα υποκείμενο.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305265A EP2236158A1 (en) | 2009-03-30 | 2009-03-30 | New therapeutic approaches for treating neuroinflammatory conditions |
| EP10711227.8A EP2413970B1 (en) | 2009-03-30 | 2010-03-29 | New therapeutic approaches for treating neuroinflammatory conditions |
| EP14156048.2A EP2735316B1 (en) | 2009-03-30 | 2010-03-29 | New therapeutic approaches for treating neuroinflammatory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118455T1 true CY1118455T1 (el) | 2017-07-12 |
Family
ID=41463183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100003T CY1118455T1 (el) | 2009-03-30 | 2017-01-03 | Νεες θεραπευτικες προσεγγισεις για θεραπεια νευροφλεγμονωδων καταστασεων |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8642566B2 (el) |
| EP (3) | EP2236158A1 (el) |
| CY (1) | CY1118455T1 (el) |
| DK (1) | DK2735316T3 (el) |
| ES (2) | ES2530847T3 (el) |
| HR (1) | HRP20161794T1 (el) |
| HU (1) | HUE032356T2 (el) |
| LT (1) | LT2735316T (el) |
| PL (1) | PL2735316T3 (el) |
| PT (1) | PT2735316T (el) |
| SI (1) | SI2735316T1 (el) |
| SM (1) | SMT201600479B (el) |
| WO (1) | WO2010115741A2 (el) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2535046A1 (en) * | 2011-06-17 | 2012-12-19 | Institut Pasteur | Use of mecamylamine in the treatment of pathogen-infected patients with central nervous system disorder |
| WO2015051152A1 (en) * | 2013-10-03 | 2015-04-09 | Leuvas Therapeutics | Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease |
| KR101809379B1 (ko) | 2016-10-13 | 2017-12-14 | 연세대학교 산학협력단 | 디오스민 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물 |
| KR20220003556A (ko) * | 2019-04-18 | 2022-01-10 | 유니버시떼 드 리에즈 | 그램-음성 박테리아 감염, 오염 및 부착물의 예방 및 처리를 위한 신규한 피리미딘 유도체 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8569277B2 (en) * | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
-
2009
- 2009-03-30 EP EP09305265A patent/EP2236158A1/en not_active Withdrawn
-
2010
- 2010-03-29 PT PT141560482T patent/PT2735316T/pt unknown
- 2010-03-29 US US13/260,773 patent/US8642566B2/en not_active Expired - Fee Related
- 2010-03-29 EP EP10711227.8A patent/EP2413970B1/en not_active Not-in-force
- 2010-03-29 SI SI201031363A patent/SI2735316T1/sl unknown
- 2010-03-29 PL PL14156048T patent/PL2735316T3/pl unknown
- 2010-03-29 DK DK14156048.2T patent/DK2735316T3/en active
- 2010-03-29 WO PCT/EP2010/054068 patent/WO2010115741A2/en active Application Filing
- 2010-03-29 ES ES10711227T patent/ES2530847T3/es active Active
- 2010-03-29 LT LTEP14156048.2T patent/LT2735316T/lt unknown
- 2010-03-29 ES ES14156048.2T patent/ES2609962T3/es active Active
- 2010-03-29 HU HUE14156048A patent/HUE032356T2/en unknown
- 2010-03-29 EP EP14156048.2A patent/EP2735316B1/en active Active
-
2016
- 2016-12-28 HR HRP20161794TT patent/HRP20161794T1/hr unknown
- 2016-12-30 SM SM201600479T patent/SMT201600479B/it unknown
-
2017
- 2017-01-03 CY CY20171100003T patent/CY1118455T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT2735316T (lt) | 2017-04-10 |
| ES2530847T3 (es) | 2015-03-06 |
| PT2735316T (pt) | 2017-01-10 |
| EP2735316A1 (en) | 2014-05-28 |
| DK2735316T3 (en) | 2017-01-23 |
| ES2609962T3 (es) | 2017-04-25 |
| WO2010115741A3 (en) | 2010-12-02 |
| EP2413970B1 (en) | 2015-01-07 |
| HRP20161794T1 (hr) | 2017-03-10 |
| SMT201600479B (it) | 2017-03-08 |
| US20120108528A1 (en) | 2012-05-03 |
| US8642566B2 (en) | 2014-02-04 |
| EP2735316B1 (en) | 2016-10-05 |
| WO2010115741A2 (en) | 2010-10-14 |
| EP2413970A2 (en) | 2012-02-08 |
| SI2735316T1 (sl) | 2017-05-31 |
| PL2735316T3 (pl) | 2017-06-30 |
| EP2236158A1 (en) | 2010-10-06 |
| HUE032356T2 (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123051T1 (el) | Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους | |
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1120102T1 (el) | Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1124495T1 (el) | Θεραπεια της amd με χρηση aav sflt-1 | |
| CY1117372T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| CY1119533T1 (el) | Νεοι θεραπευτικοι παραγοντες | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1120457T1 (el) | Αντι-ιικη θεραπεια | |
| EA201201400A1 (ru) | Композиции и способы лечения аутоиммунных и других заболеваний | |
| CY1119840T1 (el) | Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων | |
| EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
| CY1120094T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει despr036 eξenδinh-4(1-39)-lys6-nh2 για χρηση στην θεραπευτικη αγωγη μιας νευροεκφυλιστικης ασθενειας | |
| EA201300558A1 (ru) | Соединения и способы для купирования боли | |
| UA113403C2 (xx) | Спосіб підвищення ефективності folr1 терапії раку | |
| EA201791669A2 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| EA201201030A1 (ru) | 5-алкинилпиримидины | |
| EA201590930A1 (ru) | Лекарственные формы руксолитиниба с замедленным высвобождением | |
| CY1117582T1 (el) | Χρηση μιμοτοπων των α-συνουκλεϊνης επιτοπων για θεραπεια ασθενειων σωματος lewy | |
| EA201891833A1 (ru) | Комбинация для лечения амиотрофического бокового склероза или родственных болезней | |
| EA201390772A1 (ru) | Новые соли и полиморфные формы афатиниба | |
| CY1120204T1 (el) | Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο | |
| EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
| CY1118455T1 (el) | Νεες θεραπευτικες προσεγγισεις για θεραπεια νευροφλεγμονωδων καταστασεων |